Drug Discovery.
Humanized.
Javelin Biotech makes predictive drug discovery platforms that merge human biology with computational biology to improve the speed and predictive power of preclinical testing.
Pharmaceutical researchers need in vitro tools that generate human-relevant data and deliver mechanistic and clinical insights better than current in vitro tools and animal models. This is especially true for new modalities, like mRNA and gene therapies.
Next Generation In Vitro Pharmacology.
The Javelin platform combines human tissue chips, also known as organs-on-chip, with translational software to provide predictive solutions for drug discovery. Scientists can easily set-up and run experiments and quickly translate the experimental data to predictions of how drugs will behave in humans.
Products
MPS CHIPS, CONTROLLERS, AND SOFTWARE
Applications
PHARMACOKINETICS, SAFETY & TOXICOLOGY
The Challenge
Current preclinical research cannot predict how drugs will perform in humans. Simple cellular assays, such as toxicology studies, can be used for high throughput screening, but the tests are short-term, offer limited data, and are unable to reflect the complexity of full organ behavior. While animal models can be used for longer-term studies, as a platform for drug studies, they have inherent shortcomings, including human-relevance and the need for companies to manufacture larger amounts of the drug. Animal studies are expensive and can take time to execute. These challenges have contributed to a failure rate of nearly 90 percent of drugs that make it to human clinical trials, not to mention increased costs for those drugs that do succeed.
The Solution
Javelin develops platforms that provide actionable insights into how drugs perform in humans and supports quantitative decision making. Our process integrates:
01. Human Model Generation
Our tissue engineers recreate human physiology and pathophysiology outside of the human body. We develop complex human in vitro models (CIVM) such as microphysiological systems (MPS), tissue chips, and organs-on-chips which recapitulate the phenotypic and molecular functions that are important to drug discovery and development.
02. Quantification
We measure molecular changes and drug kinetics in our human CIVM and employ cutting-edge, multi-omics approaches to understand human pathophysiology at a molecular level. These human-relevant data sets unlock the potential of our algorithms and machine learning approaches.
03. Computation
Our computational biologists and data scientists use Javelin’s proprietary analytics system to translate experimental data into actionable insights. Our algorithms incorporate Systems Pharmacology, Systems Biology, and Machine Learning to discover new disease targets and combination therapies, and to estimate first in human dosing and therapeutic window.
The Impact
By integrating model generation, quantification, and computation, Javelin accelerates target discovery, lead optimization, and first-in-human dosing, delivering insights at population, sub-population, and individual levels. This can help companies make physiological and pharmacological predictions years before clinical trials and make better decisions about which compounds to advance towards IND-enabling studies, which to further study, and which to abandon.